Resources Repository
-
OrganizationWeb Portal 2024One Health Trust
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded …
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded with the objective of using research to support better decision-making in health policy. One Health Trust researchers employ a range of expertise—including economics, epidemiology, disease modeling, risk analysis, and statistics—to conduct actionable, policy-oriented research on malaria, antibiotic resistance, disease control priorities, environmental health, alcohol and tobacco, and other global health priorities. One Health Trust projects are global in scope, spanning…
Mathematical Models | Technology Assessment | Cost-Effectiveness Analysis | Health/Medicine | Climate/Environment | Global | Environmental Health | Infectious Diseases | Costing Methods | Health Outcomes | Chronic Disease/Risk | Social Determinants | Policy/Regulation | Economics/Finance | Sub-Saharan Africa | Asia & Pacific -
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Mathematical Models | Operations Research | Technology Assessment | Cost-Effectiveness Analysis | Health/Medicine | Global | Child/Nutrition | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Value of Information | Maternal/Reproductive Health | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Science/Technology -
OrganizationWeb Portal 2024Results for Development
Results for Development (R4D) was founded in 2008, with a mission to create self-sustaining systems …
Results for Development (R4D) was founded in 2008, with a mission to create self-sustaining systems that support health, educated people, while ensuring that local change agents are in the driver’s seat, and that knowledge is transformed into action. Their work supports sustainable progress in health, education and nutrition, and puts data users at the center of all efforts. They develop tools - including dashboards, scorecards and performance metrics - in a way that is designed to solve practical…
Evidence Synthesis | Technology Assessment | Health/Medicine | Climate/Environment | Global | Child/Nutrition | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Health Systems | Education/Labor -
OrganizationWeb Portal 2024American Public Health Association
The American Public Health Association (APHA), was founded in 1872 dedicated to improving the health …
The American Public Health Association (APHA), was founded in 1872 dedicated to improving the health of all U.S. residents. Two of the Association’s most important functions are advocacy for adoption by the government of the most current scientific advances relevant to public health, and public education on how to improve community health. Along with these efforts, they have also campaigned for developing well-organized health departments at both the federal and local levels. In 1966, APHA…
Evidence Synthesis | Technology Assessment | Health/Medicine | Global | Environmental Health | Child/Nutrition | Infectious Diseases | Health Outcomes | Maternal/Reproductive Health | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Health Systems | Policy/Regulation | North America -
ArticlePublication 2018Poverty Reduction & Equity Benefits of Measles, Rotavirus and Pneumococcal Vaccines in LMICs
This study uses the extended cost effectiveness analysis (ECEA) to evaluate the impact of immunization …
This study uses the extended cost effectiveness analysis (ECEA) to evaluate the impact of immunization against measles, severe pneumococcal disease and severe rotavirus for birth cohorts vaccinated over 2016–2030 for three scenarios in 41 Gavi-eligible countries: no immunization, current immunization coverage forecasts and the current immunization coverage enhanced with funding support. Following the distribution of the cases by socioeconomic group, the study found that the number of catastrophic health costs (CHC) cases attributable to measles,…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Global | Child/Nutrition | Infectious Diseases | Priority Setting/Ethics -
OrganizationWeb Portal 2024PATH
PATH is an international nonprofit organization that has been translating ideas into health solutions for …
PATH is an international nonprofit organization that has been translating ideas into health solutions for 40 years, with a focus on child survival, maternal and reproductive health, and infectious diseases. PATH mobilizes partners around the world in order to take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. PATH takes a multidimensional approach to solving health challenges, with work spanning five platforms: Vaccines to give children a…
Technology Assessment | Cost-Effectiveness Analysis | Health/Medicine | Global | Child/Nutrition | Infectious Diseases | Costing Methods | Health Outcomes | Maternal/Reproductive Health | Social Determinants | Health Systems | Sub-Saharan Africa | Asia & Pacific -
ArticlePublication 2019Systematic Review of Economic Evaluations of Vaccination Strategies Against Tuberculosis
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited …
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited and varies by age, so a valid cost-effectiveness study is needed to assist decision-makers in the implementation of cost-effective strategies for BCG vaccination. Using the Quality of Health Economic Studies (QHES) instrument, the authors assessed the quality of published studies involving economic evaluations of BCG vaccination strategies in a variety of regions, target populations, and vaccine types. Most of the…
Evidence Synthesis | Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Global | Infectious Diseases -
OrganizationWeb Portal 2024Global Health Cost Consortium
The Global Health Cost Consortium (GHCC) is a new three-year initiative funded by the Bill …
The Global Health Cost Consortium (GHCC) is a new three-year initiative funded by the Bill and Melinda Gates Foundation to provide decision-makers with improved resources to estimate the costs of HIV and tuberculosis (TB) programs. GHCC’s goal is to increase the efficiency and effectiveness of HIV and TB prevention and treatment, and drive greater value for money of investments to tackle HIV and TB in low and middle-income countries, by improving the availability, quality, timing, and…
Evidence Synthesis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health/Medicine | Global | Infectious Diseases | Costing Methods | Health Systems -
ArticlePublication 2023Cost-Effectiveness of Novel TB Vaccines: A Modeling Study
A modeling study assessed future costs, cost-savings, and cost-effectiveness of introducing novel tuberculosis (TB) vaccines …
A modeling study assessed future costs, cost-savings, and cost-effectiveness of introducing novel tuberculosis (TB) vaccines in 105 low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies, compared to a ‘no-new-vaccine’ counterfactual. Vaccine scenarios considered two vaccine product profiles (one targeted at infants, one at adolescents/adults), both assumed to prevent progression to active TB. Vaccine introduction was estimated to require substantial near-term resources, offset by future cost-savings from averted TB burden.…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Global | Infectious Diseases | Economics/Finance